Catalog Number:
(STMC100-0930)
Limited time offers
Supplier:
STEMCELL Technologies
Description:
Interleukin 34 (IL-34) is well known for its ability to induce the formation of colony-forming unit macrophages in human bone marrow cell cultures (Foucher <i>et al.</i>; Wei <i>et al.</i>). This dimeric glycoprotein is a member of the short-chain helical hematopoietic cytokine family (Baghdadi <i>et al.</i>; Foucher <i>et al.</i>), and exists in two isoforms that differ by a single glutamine (Chen <i>et al.</i>; Foucher et al; Wei <i>et al.</i>). IL-34 interacts with M-CSF to trigger tyrosine phosphorylation of the receptor and ERK1/2 pathways. (Wang <i>et al.</i>; Wei <i>et al.</i>). It is expressed in many tissues (heart, brain, lung, liver, kidney, thymus, testes, ovary, small intestine, prostate, and colon), with the highest expression in the spleen. In combination with RANKL, IL-34 induces osteoclast differentiation (Chen <i>et al.</i>; Foucher <i>et al.</i>). IL-34 expression is decreased in Alzheimer’s disease and atopic dermatitis, while high levels of IL-34 are found in many types of cancer correlated with poor prognosis, chronic heart failure or coronary artery disease, inflammatory bowel disease, influenza A infection, during acute liver transplant rejection or in non-alcoholic fatty liver disease, and with rheumatoid arthritis (Baghdadi <i>et al.</i>). It is therefore a possible pharmacological target for treating bone or inflammatory diseases (Chen <i>et al.</i>). This protein contains a His-residue tag at the carboxyl end of the polypeptide chain, and the protein was purified as a homodimer consisting of 39 kDa monomers (Lin <i>et al.</i>).
UOM:
1 * 100 µG
